Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
暂无分享,去创建一个
[1] K. Bagshawe. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer , 2006, Expert review of anticancer therapy.
[2] V. Rohmer,et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Jacques Barbet,et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] W. Mcbride,et al. Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft , 2005, Clinical Cancer Research.
[5] F. Kraeber-Bodéré,et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.
[6] Chien-Hsing Chang,et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody , 2005, Nature Medicine.
[7] William McBride,et al. Pretargeting of Carcinoembryonic Antigen–Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells , 2005, Clinical Cancer Research.
[8] W. Mcbride,et al. Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods , 2005, Clinical Cancer Research.
[9] B. Ghadimi,et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] I. Pastan,et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] W. Mcbride,et al. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody , 2005, Leukemia.
[12] D. Goldenberg,et al. Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal , 2005, Expert review of clinical immunology.
[13] Bruce D Cheson,et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development , 2005, Clinical Cancer Research.
[14] S. Shen,et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] D. Goldenberg,et al. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] B. Dupas,et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.
[17] J. Armitage,et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Zelenetz,et al. The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy , 2004, Clinical Cancer Research.
[19] Sur Sharma,et al. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer , 2004, Expert opinion on biological therapy.
[20] J. Winter. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. , 2004, Clinical lymphoma.
[21] G. Maira,et al. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[22] G. G. Miller,et al. Preliminary Results of Nanopharmaceuticals Used in the Radioimmunotherapy of Ovarian Cancer , 2004, 2004 International Conference on MEMS, NANO and Smart Systems (ICMENS'04).
[23] J. Vose,et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2004, Blood.
[24] F. Malavasi,et al. Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin? , 2004, Gynecologic oncology.
[25] M. Rusckowski,et al. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] M. Brechbiel,et al. Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.
[27] S. Larson,et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] D. Goldenberg,et al. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression , 2004, International journal of cancer.
[29] Paul J Yazaki,et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] O. de Cobelli,et al. Localization of avidin in superficial bladder cancer: a potentially new approach for radionuclide therapy. , 2003, European urology.
[31] R. Fisher,et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. , 2003, Blood.
[32] W. Mcbride,et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] K. Auditore-Hargreaves,et al. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] D. Modrak,et al. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] F. Kraeber-Bodéré,et al. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] W. McBride,et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] M. Welch,et al. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] M. Chelli,et al. A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. , 2003, Journal of Medicinal Chemistry.
[39] W. Oyen,et al. Pretargeted radioimmunotherapy of cancer: progress step by step. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] T. Waldmann,et al. Immunotherapy: past, present and future , 2003, Nature Medicine.
[41] W. McBride,et al. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[42] J. Schlom,et al. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] W. Mcbride,et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen. , 2002, Bioconjugate chemistry.
[44] L. Gordon,et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] W. McBride,et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. , 2002, Molecular cancer therapeutics.
[46] D. Goldenberg. Targeted therapy of cancer with radiolabeled antibodies. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[47] F. Kraeber-Bodéré,et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. , 2002, Molecular cancer therapeutics.
[48] P. Caliceti,et al. Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study , 2002, British Journal of Cancer.
[49] Damon L. Meyer,et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. , 2001, Blood.
[50] C. Meares,et al. Advances in pretargeting biotechnology. , 2001, Biotechnology advances.
[51] J. Vose,et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] J. Barbet,et al. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[53] A. Magener,et al. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. , 2001, Cancer research.
[54] A. Scott,et al. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] E. Gautherot,et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[56] P. Beaumier,et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[57] D. Fisher,et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. , 2000, Cancer biotherapy & radiopharmaceuticals.
[58] M. Goris,et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] J. Douillard,et al. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[60] M. Goris,et al. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. , 1999, Cancer biotherapy & radiopharmaceuticals.
[61] M Bardiès,et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[62] F. Kraeber-Bodéré,et al. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[63] W. Oyen,et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. , 1999, Cancer research.
[64] F. D. De Braud,et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin , 1999, European Journal of Nuclear Medicine.
[65] M. Ferrari,et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients , 1999, European Journal of Nuclear Medicine.
[66] E. Perez,et al. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. , 1998, Anticancer research.
[67] E. Gautherot,et al. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[68] B. Wessels,et al. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[69] C. Meares,et al. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[70] F. D. De Braud,et al. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy , 1998, European Journal of Nuclear Medicine.
[71] D. Goldenberg,et al. Experimental studies on the role of antibody fragments in cancer radio‐immunotherapy: Influence of radiation dose and dose rate on toxicity and anti‐tumor efficacy , 1998, International journal of cancer.
[72] D Huglo,et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[73] A. Casadevall. Antibody-based therapies as anti-infective agents. , 1998, Expert opinion on investigational drugs.
[74] E. Gautherot,et al. Therapy for colon carcinoma xenografts with bispecific antibody‐targeted, iodine‐131‐labeled bivalent hapten , 1997, Cancer.
[75] W. Mcbride,et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development. , 1997, Bioconjugate chemistry.
[76] G. Fulci,et al. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. , 1997, Cancer research.
[77] E. Brambilla,et al. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[78] M. Juweid,et al. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy. , 1997, Journal of nuclear medicine technology.
[79] M Bardiès,et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[80] F. Fazio,et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[81] M. Schlumberger,et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[82] G. Denardo,et al. Radioimmunotherapy: recent results and future directions. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] P. Schubiger,et al. Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. , 1996, Bioconjugate chemistry.
[84] H. Sakahara,et al. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[85] J. Chatal,et al. Pretargetted imaging of colorectal cancer recurrences using an 111In‐labelled bivalent hapten and a bispecific antibody conjugate , 1994, Nuclear medicine communications.
[86] P. Beaumier,et al. PRECLINICAL EVALUATION OF AN ANTI-TUMOR MONCLONAL ANTIBODY/ STREPTAVIDIN CONJUGATE FOR PRETARGETED 90Y RADIOIMMUNOTHERAPY IN A MOUSE XENOGRAFT MODEL , 1994 .
[87] J. Weinstein,et al. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. , 1994, Cancer research.
[88] E. Gautherot,et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[89] C. Meares,et al. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[90] J. Slater,et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. , 1991, Cancer research.
[91] L. Lopalco,et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. , 1991, Cancer research.
[92] H. Kalofonos,et al. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[93] A. Siccardi,et al. Intraperitoneal radio‐localization of tumors pre‐targeted by biotinylated monoclonal antibodies , 1990, International journal of cancer.
[94] E. Gautherot,et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[95] C. Meares,et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[96] F. Virzi,et al. Investigations of avidin and biotin for imaging applications. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[97] K. Dakshinamurti,et al. Purification and characterization of human serum biotinidase. , 1986, The Journal of biological chemistry.
[98] C. Meares,et al. Antibodies against metal chelates , 1985, Nature.
[99] D. Goldenberg,et al. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[100] C. Divgi,et al. Current status of therapy of solid tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[101] M. Zalutsky. Current status of therapy of solid tumors: brain tumor therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[102] W. Mcbride,et al. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[103] K. Lamborn,et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6 , 2002, The Prostate.
[104] P. Beaumier,et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.